Seqens Seqens

X
[{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical Reports that Clinical Trial with Remygen[\u00ae] is Expanded to Evaluate Prevention of Hypoglycaemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MDbio Wellness","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MDbio Starts Clinical Trials for Pharmaceutical-Grade Products That Target Sleeplessness, Stress and Pain","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Sleep","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for NCGC00024546-01

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            MDsleep (cannabis sativa oil), also known as hemp seed oil, is a lightweight oil cold-pressed from the seeds of the Cannabis sativa plant. It’s been used for centuries in cooking, as well as topically to help with a wide range of skin concerns.

            Lead Product(s): Cannabis Sativa Oil,Gamma-Aminobutyric Acid,L-Theanine

            Therapeutic Area: Sleep Product Name: MDsleep

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.

            Lead Product(s): Gamma-Aminobutyric Acid,Alprazolam

            Therapeutic Area: Endocrinology Product Name: Remygen

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY